HIF-1α Reduction by Lowering Intraocular Pressure Alleviated Retinal Neovascularization

Biomolecules. 2023 Oct 17;13(10):1532. doi: 10.3390/biom13101532.

Abstract

Hypoxia-induced retinal neovascularization is a leading cause of blindness worldwide. Oxygen-induced retinopathy (OIR) mouse, a well-established angiogenesis model, has been extensively used to evaluate the effect of anti-angiogenic agents through intravitreal injection. Here, we serendipitously found that the needles used for intravitreal injection caused an unexpected "anti-angiogenic" effect in the OIR mice. To evaluate the effects of various intravitreal puncture sizes on retinal neovascularization and explore the potential underlying mechanism, intravitreal punctures using 0.5 mm (25 G), 0.3 mm (30 G), or 0.21 mm (33 G) needles were performed in OIR mice. Compared with 0.3 mm and 0.21 mm puncture, the 0.5 mm puncture remarkably suppressed the formation of pathological angiogenesis, inhibited vascular leakage, and remodeled the retinal vasculature. Mechanistically, the 0.5 mm puncture induced a substantial reduction in intraocular pressure (IOP), leading to an improvement in oxygen partial pressure (pO2) and significant reduction in Hif1a expression, resulting in resolution of angiogenic and inflammatory responses. Furthermore, IOP-lowering drugs, Travatan or Azarga, also promoted the alleviation of hypoxia and exhibited a potent anti-angiogenesis efficacy. Our study revealed an acute and significant reduction in IOP caused by a large puncture, which could remarkably suppress HIF-1α-mediated retinal neovascularization, indicating that lowering IOP may be a promising therapeutic avenue for treating retinal neovascular diseases.

Keywords: hypoxia-inducible factor-1 alpha (HIF-1α); intraocular pressure (IOP); intravitreal injection; oxygen-induced retinopathy (OIR); retinal neovascularization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Hypoxia / drug therapy
  • Hypoxia / metabolism
  • Intraocular Pressure
  • Mice
  • Mice, Inbred C57BL
  • Neovascularization, Pathologic / drug therapy
  • Oxygen / therapeutic use
  • Retinal Diseases*
  • Retinal Neovascularization* / metabolism

Substances

  • Oxygen
  • Angiogenesis Inhibitors

Grants and funding

Xialin Liu received funding from the National Natural Science Foundation of China (No. 82271095) and Guangdong Provincial Key Area R&D Program (No. 2023B1111050004). Chang He received funding from the National Natural Science Foundation of China (No. 82171068), Natural Science Foundation of Guangdong Province, China (No. 2019B151502006).